Bringing the fundamentals into focus…
Back to Iovance Biotherapeutics, Inc.
How Iovance Biotherapeutics, Inc. stacks up
IOVA · against 261 other Healthcare companies of similar size
Overall
30/ 100
Near the bottom of its peers.
Ranked #235 of 262 · scores higher than 9% of peers
Bars: peers in each 10-point band of the overall score36 peers with an overall score of 30–39, including IOVA · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around IOVA| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | 100 | 0 / 2 | ||
| 2 | 2.1B USD | 96 | 96 | 99 | 93 | 0 / 2 | |
| 2 | 15.6B DKK (≈$2.3B) | 96 | 96 | 99 | 96 | 0 / 2 | |
| 4 | 37.3B HKD (≈$4.8B) | 90 | 99 | 98 | 84 | 0 / 2 | |
| 5 | 19.7B HKD (≈$2.5B) | 84 | 84 | 98 | 87 | 0 / 2 | |
| 228 | 6.0B USD | 32 | 8 | 91 | 16 | 2 / 2 | |
| 233 | 3.7B USD | 31 | 8 | 8 | 13 | 0 / 2 | |
| 233 | 2.5B USD | 31 | 8 | 64 | 16 | 1 / 2 | |
| 235 | 6.0B USD | 30 | 8 | 82 | 28 | 2 / 2 | |
| 235 | 4.0B USD | 30 | 8 | — | 16 | 0 / 2 | |
| 235 | 5.7B USD | 30 | 8 | 90 | 13 | 2 / 2 | |
| 235 | 7.8B USD | 30 | 8 | 4 | 20 | 0 / 2 | |
| 239 | 4.6B USD | 29 | 8 | 5 | 5 | 0 / 2 | |
| 239 | 2.0B USD | 29 | 8 | 65 | 22 | 2 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score